Equibles does not estimate personal net worth.
Get an email with a short summary when Voyager Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get VYGR alertsRobin Swartz is recorded as CFO at Voyager Therapeutics, Inc. (VYGR) since April 12, 2024 and COO at Voyager Therapeutics, Inc. (VYGR). The newest filing on record that lists Robin Swartz as COO at Voyager Therapeutics, Inc. (VYGR) is dated April 28, 2026. Voyager Therapeutics, Inc. reported in an 8-K filed October 21, 2026 that Robin Swartz was appointed President of the Company, effective October 20, 2026. Voyager Therapeutics, Inc. reported in an 8-K filed April 21, 2026 that Robin Swartz was appointed principal financial officer and treasurer, effective May 8, 2026. Voyager Therapeutics, Inc. reported in an 8-K filed April 2, 2024 that Robin Swartz was appointed principal financial officer and principal accounting officer, effective April 12, 2024. The proxy statement of Voyager Therapeutics, Inc. reports total compensation of $1,454,300 for Robin Swartz in fiscal 2025, including a base salary of $520,190. Disclosed compensation is on record for 2 fiscal years. Robin Swartz has spoken on 1 earnings call across 1 company, most recently for Voyager Therapeutics, Inc. on May 13, 2024. Voyager Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Voyager Therapeutics, Inc. includes Alfred Sandrock (CEO and Board Member), Alfred Sandrock, M.D., Ph.D. (CEO and Board Member), Michael Higgins (CEO and Board Member) and 7 others.
“On October 20, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Voyager Therapeutics, Inc. (the “Company”) appointed Robin Swartz, the Company’s Chief Business Officer and Chief Operating Officer, to serve as President of the Company, effective immediately.”
“on April 20, 2026, the board of directors of the Company appointed Robin Swartz to assume the roles of principal financial officer and treasurer of the Company, effective as of the Effective Time.”
“We were very pleased with the advancement of our Neurocrine programs and the achievement of the DC milestone. However, we don't provide guidance on potential future milestone payments across our 13 partner programs.”
2026-05-08–present
2024-04-12–present
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
COO, CFO
2024-04-12–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Voyager Therapeutics, Inc. (VYGR) | Chief Business Officer & Chief Operating Officer | $520,190 | $1,454,300 |
| 2024 | Voyager Therapeutics, Inc. (VYGR) | Chief Business Officer & Chief Operating Officer | $490,745 | $1,613,804 |
